Quelle est la durée typique du traitement au téniposide ?
La durée varie, mais elle est généralement de plusieurs cycles de traitement.
Durée du traitementCycles de chimiothérapie
#3
Comment le téniposide est-il surveillé pendant le traitement ?
La surveillance inclut des tests sanguins réguliers et des évaluations cliniques.
SurveillanceTests sanguins
#4
Quelles sont les alternatives au téniposide ?
D'autres agents comme la doxorubicine ou le cyclophosphamide peuvent être utilisés.
DoxorubicineCyclophosphamide
#5
Le téniposide nécessite-t-il des ajustements de dose ?
Oui, des ajustements peuvent être nécessaires en fonction de la tolérance et des effets secondaires.
Ajustement de doseTolérance
Complications
5
#1
Quelles complications peuvent survenir avec le téniposide ?
Des complications comme l'infection, l'anémie et des saignements peuvent survenir.
ComplicationsInfection
#2
Le téniposide peut-il causer des problèmes cardiaques ?
Oui, il existe un risque de cardiotoxicité, surtout à fortes doses.
CardiotoxicitéDoses élevées
#3
Comment gérer une infection liée au téniposide ?
Un traitement antibiotique et une surveillance étroite sont nécessaires.
InfectionTraitement antibiotique
#4
Le téniposide peut-il affecter la fertilité ?
Oui, il peut avoir un impact sur la fertilité, surtout chez les femmes.
FertilitéImpact
#5
Quels signes indiquent une complication grave ?
Des signes comme des saignements inhabituels ou une fièvre élevée doivent alerter.
Signes d'alerteSaignements
Facteurs de risque
5
#1
Qui est à risque d'effets secondaires graves ?
Les patients avec des antécédents de maladies hématologiques sont à risque accru.
Antécédents médicauxMaladies hématologiques
#2
L'âge influence-t-il la tolérance au téniposide ?
Oui, les personnes âgées peuvent avoir une tolérance réduite au traitement.
ÂgeTolérance
#3
Les antécédents de chimiothérapie augmentent-ils les risques ?
Oui, les antécédents de chimiothérapie peuvent augmenter le risque d'effets secondaires.
Antécédents de chimiothérapieRisques
#4
Le statut immunitaire affecte-t-il le traitement ?
Oui, un statut immunitaire affaibli augmente le risque d'infections et de complications.
Statut immunitaireComplications
#5
Y a-t-il des interactions médicamenteuses à surveiller ?
Oui, des interactions avec des anticoagulants ou d'autres chimiothérapies doivent être surveillées.
Interactions médicamenteusesAnticoagulants
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Téniposide : Questions médicales les plus fréquentes",
"headline": "Téniposide : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Téniposide : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-02",
"dateModified": "2024-11-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Téniposide"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Glucosides",
"url": "https://recherchemedicale.com/mesh/D005960",
"about": {
"@type": "MedicalCondition",
"name": "Glucosides",
"code": {
"@type": "MedicalCode",
"code": "D005960",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D09.408.348"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Téniposide",
"alternateName": "Teniposide",
"code": {
"@type": "MedicalCode",
"code": "D013713",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Rahul Rana",
"url": "https://recherchemedicale.com/author/Rahul%20Rana",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada."
}
},
{
"@type": "Person",
"name": "Ravi N Vellanki",
"url": "https://recherchemedicale.com/author/Ravi%20N%20Vellanki",
"affiliation": {
"@type": "Organization",
"name": "Princess Margaret Cancer Centre and, The Campbell Family Institute for Cancer Research Institution, Departments of Radiation Oncology and Medical Biophysics, University Health Network, 101, College St., Toronto, Ontario, M5G 1L7, Canada."
}
},
{
"@type": "Person",
"name": "Bradly G Wouters",
"url": "https://recherchemedicale.com/author/Bradly%20G%20Wouters",
"affiliation": {
"@type": "Organization",
"name": "Princess Margaret Cancer Centre and, The Campbell Family Institute for Cancer Research Institution, Departments of Radiation Oncology and Medical Biophysics, University Health Network, 101, College St., Toronto, Ontario, M5G 1L7, Canada."
}
},
{
"@type": "Person",
"name": "Mark Nitz",
"url": "https://recherchemedicale.com/author/Mark%20Nitz",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada."
}
},
{
"@type": "Person",
"name": "Yi-Xia Wang",
"url": "https://recherchemedicale.com/author/Yi-Xia%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Hematology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Teniposide-intensified hematopoietic stem cell transplantation with acute graft versus host disease prophylaxis with anti-thymocyte globulin provides good results in high-risk or refractory recurrent hematopoietic malignant diseases.",
"datePublished": "2021-Nov-00",
"url": "https://recherchemedicale.com/article/34872304",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.21037/apm-21-3122"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tellurophene-Tagging of Teniposide Facilitates Monitoring by Mass Cytometry.",
"datePublished": "2022-09-20",
"url": "https://recherchemedicale.com/article/36040838",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cbic.202200284"
}
},
{
"@type": "ScholarlyArticle",
"name": "First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.",
"datePublished": "2023-08-11",
"url": "https://recherchemedicale.com/article/37568079",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-023-11268-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "AL amyloidosis: untangling new therapies.",
"datePublished": "2021-12-10",
"url": "https://recherchemedicale.com/article/34889374",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1182/hematology.2021000305"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia.",
"datePublished": "2023-05-29",
"url": "https://recherchemedicale.com/article/37356294",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.compbiomed.2023.107078"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Glucides",
"item": "https://recherchemedicale.com/mesh/D002241"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hétérosides",
"item": "https://recherchemedicale.com/mesh/D006027"
},
{
"@type": "ListItem",
"position": 4,
"name": "Glucosides",
"item": "https://recherchemedicale.com/mesh/D005960"
},
{
"@type": "ListItem",
"position": 5,
"name": "Téniposide",
"item": "https://recherchemedicale.com/mesh/D013713"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Téniposide - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Téniposide",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-02-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Téniposide",
"description": "Comment le téniposide est-il administré ?\nQuels tests sont nécessaires avant traitement ?\nLe téniposide est-il utilisé pour tous les types de cancer ?\nQuels marqueurs tumoraux sont surveillés ?\nY a-t-il des contre-indications au téniposide ?",
"url": "https://recherchemedicale.com/mesh/D013713#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Téniposide",
"description": "Quels sont les effets secondaires courants du téniposide ?\nLe téniposide cause-t-il des douleurs ?\nComment reconnaître une réaction allergique au téniposide ?\nLe téniposide affecte-t-il le système immunitaire ?\nQuels symptômes indiquent une surdose de téniposide ?",
"url": "https://recherchemedicale.com/mesh/D013713#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Téniposide",
"description": "Comment minimiser les effets secondaires du téniposide ?\nY a-t-il des précautions à prendre avant le traitement ?\nComment prévenir les infections pendant le traitement ?\nDes suppléments sont-ils recommandés avec le téniposide ?\nLe suivi médical est-il important après le traitement ?",
"url": "https://recherchemedicale.com/mesh/D013713#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Téniposide",
"description": "Le téniposide est-il utilisé seul ou en combinaison ?\nQuelle est la durée typique du traitement au téniposide ?\nComment le téniposide est-il surveillé pendant le traitement ?\nQuelles sont les alternatives au téniposide ?\nLe téniposide nécessite-t-il des ajustements de dose ?",
"url": "https://recherchemedicale.com/mesh/D013713#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Téniposide",
"description": "Quelles complications peuvent survenir avec le téniposide ?\nLe téniposide peut-il causer des problèmes cardiaques ?\nComment gérer une infection liée au téniposide ?\nLe téniposide peut-il affecter la fertilité ?\nQuels signes indiquent une complication grave ?",
"url": "https://recherchemedicale.com/mesh/D013713#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Téniposide",
"description": "Qui est à risque d'effets secondaires graves ?\nL'âge influence-t-il la tolérance au téniposide ?\nLes antécédents de chimiothérapie augmentent-ils les risques ?\nLe statut immunitaire affecte-t-il le traitement ?\nY a-t-il des interactions médicamenteuses à surveiller ?",
"url": "https://recherchemedicale.com/mesh/D013713#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le téniposide est-il administré ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le téniposide est généralement administré par voie intraveineuse."
}
},
{
"@type": "Question",
"name": "Quels tests sont nécessaires avant traitement ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des évaluations de la fonction hépatique sont requis."
}
},
{
"@type": "Question",
"name": "Le téniposide est-il utilisé pour tous les types de cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il est principalement utilisé pour les leucémies et certains sarcomes."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont surveillés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs comme le CD34 peuvent être surveillés pour évaluer la réponse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des contre-indications au téniposide ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les allergies au médicament et certaines infections actives sont des contre-indications."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants du téniposide ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, vomissements et fatigue."
}
},
{
"@type": "Question",
"name": "Le téniposide cause-t-il des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut provoquer des douleurs abdominales ou des douleurs au site d'injection."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique au téniposide ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent éruption cutanée, démangeaisons et difficulté à respirer."
}
},
{
"@type": "Question",
"name": "Le téniposide affecte-t-il le système immunitaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut entraîner une immunosuppression, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose de téniposide ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des saignements excessifs et des infections fréquentes peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment minimiser les effets secondaires du téniposide ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hydratation adéquate et l'utilisation de médicaments antiémétiques peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des précautions à prendre avant le traitement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer le médecin des allergies et des médicaments en cours est crucial."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections pendant le traitement ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les foules et pratiquer une bonne hygiène sont des mesures préventives."
}
},
{
"@type": "Question",
"name": "Des suppléments sont-ils recommandés avec le téniposide ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consulter un médecin avant de prendre des suppléments est conseillé."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il important après le traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour surveiller les effets à long terme."
}
},
{
"@type": "Question",
"name": "Le téniposide est-il utilisé seul ou en combinaison ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est souvent utilisé en combinaison avec d'autres agents chimiothérapeutiques."
}
},
{
"@type": "Question",
"name": "Quelle est la durée typique du traitement au téniposide ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie, mais elle est généralement de plusieurs cycles de traitement."
}
},
{
"@type": "Question",
"name": "Comment le téniposide est-il surveillé pendant le traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance inclut des tests sanguins réguliers et des évaluations cliniques."
}
},
{
"@type": "Question",
"name": "Quelles sont les alternatives au téniposide ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "D'autres agents comme la doxorubicine ou le cyclophosphamide peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Le téniposide nécessite-t-il des ajustements de dose ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des ajustements peuvent être nécessaires en fonction de la tolérance et des effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le téniposide ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme l'infection, l'anémie et des saignements peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le téniposide peut-il causer des problèmes cardiaques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il existe un risque de cardiotoxicité, surtout à fortes doses."
}
},
{
"@type": "Question",
"name": "Comment gérer une infection liée au téniposide ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement antibiotique et une surveillance étroite sont nécessaires."
}
},
{
"@type": "Question",
"name": "Le téniposide peut-il affecter la fertilité ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut avoir un impact sur la fertilité, surtout chez les femmes."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des saignements inhabituels ou une fièvre élevée doivent alerter."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires graves ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec des antécédents de maladies hématologiques sont à risque accru."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la tolérance au téniposide ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir une tolérance réduite au traitement."
}
},
{
"@type": "Question",
"name": "Les antécédents de chimiothérapie augmentent-ils les risques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de chimiothérapie peuvent augmenter le risque d'effets secondaires."
}
},
{
"@type": "Question",
"name": "Le statut immunitaire affecte-t-il le traitement ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un statut immunitaire affaibli augmente le risque d'infections et de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des interactions médicamenteuses à surveiller ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interactions avec des anticoagulants ou d'autres chimiothérapies doivent être surveillées."
}
}
]
}
]
}
Princess Margaret Cancer Centre and, The Campbell Family Institute for Cancer Research Institution, Departments of Radiation Oncology and Medical Biophysics, University Health Network, 101, College St., Toronto, Ontario, M5G 1L7, Canada.
Princess Margaret Cancer Centre and, The Campbell Family Institute for Cancer Research Institution, Departments of Radiation Oncology and Medical Biophysics, University Health Network, 101, College St., Toronto, Ontario, M5G 1L7, Canada.
Department of Biotherapy Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China yysysu@163.com ye_linsen@163.com qinyf6@mail.sysu.edu.cn.
Teniposide, as a more potent inhibitor of topoisomerase II compared with etoposide, shows less damage on hematopoietic stem cells. Few data are available on teniposide in hematopoietic stem cell trans...
A retrospective single arm study was conducted to confirm the feasibility of teniposide (300 mg/m2) -intensified HSCT in the treatment of high-risk or refractory recurrent hematopoietic malignant dise...
All patients achieved myeloid engraftment at a median of 13 days (range, 9-28 days), platelet engraftment at 15.5 days (range, 6-142 days), with a cumulative incidence (CI) of platelet engraftment of ...
For patients with high-risk or refractory recurrent hematopoietic malignant disease, teniposide-based conditioning regimens followed by allo-HSCT can be considered as an alternative therapy with encou...
Target engagement and the biodistribution of exogenously administered small molecules is rarely homogenous. Methods to determine the biodistribution at the cellular level are limited by the ability to...
This study aimed to compare the efficacy and safety of high-dose methotrexate (HD-MTX) versus teniposide (TEN) in patients with newly diagnosed immunocompetent primary central nervous system lymphomas...
The study included immunocompetent, adult patients with newly diagnosed PCNSL at 22 centers in China from 2007 to 2016. The patients received HD-MTX or TEN as first-line induction therapy. The objecti...
A total of 96 patients were eligible: 62 received HD-MTX, while 34 received teniposide. The overall response rate was 73.2% and 72.7% in the MTX and the TEN cohorts, respectively (P = 0.627). The medi...
This was the first multicenter study using TEN as the main agent compared with HD-MTX in newly diagnosed primary CNS lymphoma. The TEN-based regimen was non-inferior to the HD-MTX-based regimen with s...
This study provided Class III evidence that the teniposide-based regimen was non-inferior to high-dose methotrexate - based regimen with similar overall responses and long-time survival in immunocompe...
Systemic light chain (AL) amyloidosis is a protein misfolding disorder characterized by the deposition of abnormal immunoglobulin light chains in fibrillary aggregates, resulting in end-organ damage. ...
TP53 mutation and hypoxia play an essential role in cancer progression. However, the metabolic reprogramming and tumor microenvironment (TME) heterogeneity mediated by them are still not fully underst...
The multi-omics data of 32 cancer types and immunotherapy cohorts were acquired to comprehensively characterize the metabolic reprogramming pattern and the TME across cancer types and explore immunoth...
First, we identified metabolic subtype A (hypoxia-TP53 mutation subtype) and metabolic subtype B (non-hypoxia-TP53 wildtype subtype) in hepatocellular carcinoma (HCC) and showed that metabolic subtype...
Metabolic alteration mediated by hypoxia and TP53 mutation is associated with TME modulation and tumor progression across cancer types. In this study, we analyzed the role of metabolic alteration in c...
This case series describes the safety and efficacy of superselective intra-arterial (IA) cerebral infusion of teniposide for the treatment of patients with glioma, to provide new ideas and methods for...
12 patients with glioma who were previously treated with standard therapy were treated with superselective IA cerebral infusion of teniposide. Patients received at least two cycles of treatment (one c...
No significant differences in biochemical indexes and Karnofsky performance status (KPS) score were observed before and after treatment, and no evident adverse events occurred (P>0.05). In a recent re...
This small series suggests that superselective IA cerebral infusion of teniposide may be a safe and effective therapy in the multimodal treatment of malignant glioma and warrants further study in larg...
There are limited data on the efficacy and tolerability of VCD chemotherapy in transplant-non-eligible (TNE) newly diagnosed myeloma (NDMM) patients. In this retrospective study, we set out to evaluat...
The primary end point was overall response rate (ORR). Secondary outcomes included event-free survival (EFS), overall survival (OS) and adverse events (AEs)....
In a total cohort of 158 patients, ORR for total cohort was 72.1%. Median EFS was 10.5 months, and for subgroups by age (<75:11.7 vs ≥75:10.3 months, P = .124), by Charlson Co-morbidity Index (CCI) (<...
This study demonstrated a good ORR achieved from fixed duration VCD, which was reasonably well tolerated. This was followed by modest median EFS. We envisage that the latter may be improved in this pa...
Cytogenetic abnormalities are a recognized factor in the pathogenesis of multiple myeloma (MM). While chromosomal translocations involving the IGH gene have been investigated and reported, the implica...
The present study aimed to investigate the curative effect of high-dose methotrexate (HD-MTX) combined with teniposide (Vm26) vs. HD-MTX alone in the treatment of primary central nervous system lympho...
This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or car...